A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

Trial Profile

A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms ORL03
  • Sponsors UNICANCER
  • Most Recent Events

    • 11 Sep 2015 Primary endpoint (Disease control) has been met as results published at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top